Answers are grounded in this paper and cite their sources.
Systemic cobalt toxicity, including sensorineural hearing loss, may occur in patients with cobalt-chromium (CoCr) hip prostheses. This report describes a 45-year-old woman who underwent unilateral total hip revision surgery due to mechanical failure of her original implant. Intraoperative findings included fractures of her original ceramic prosthesis that were debrided. A new CoCr dual mobility liner and femoral head were implanted. Within a few months postoperatively, she developed sensorineural hearing loss and was diagnosed with markedly elevated plasma cobalt and chromium concentrations. She underwent a second revision procedure, but her hearing loss persisted. After treatment with prednisone, succimer, N-acetylcysteine (NAC), and hyperbaric oxygen therapy, her hearing acuity improved. For patients with arthroprosthetic cobalt toxicity, prosthesis explantation and revision are primary treatments that often result in symptom improvement, but patients who experience persistent ototoxicity may benefit from additional therapies to improve symptoms and reduce the systemic cobalt burden.
No takes yet. Share an insight, caveat, or question.
Johnson-Arbor et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: